Skip to content
April 24, 2024

Equity.Guru

Investment information for the new generation

Search

Lexaria Biosciences

Closing the Diabetic Loop Before we get into this week’s sector roundup, let’s talk about diabetes. I am a sucker for sweets, so much so that I was diagnosed…
Smart Watch, Healthy Heart   There was an opportunity for a pun in the headline and I took it. In this week’s sector roundup, we are going to be…
Digital Medicine Society   The world is on fire, inflation is through the roof, and there is a literal war occurring in Ukraine. While I believe it is important…
Old Memories I have always been a sucker for nostalgia. When I first started writing for Equity Guru, I spent most of my time covering biotechnology companies. Whether they…
@presley1000 @ChrisParry nahh he’ll probably take some of the credit lol — dielawn (@Dyro01676) January 9, 2017 There’s an old way of thinking in the marketing game that, if…
I’ve spent many column inches talking about how I feel like Lexaria (LXX.C is an incomplete business. That is, incomplete inasmuch as there’s no business in their business. They’ve…
Sometimes I can’t even. For a few years now, Lexaria Bioscience (LXX.C) has crept around in the background of the Canadian bongosphere. It had a chequered start, partnering up with…